Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aviptadil - Relief Therapeutics Holdings

Drug Profile

Aviptadil - Relief Therapeutics Holdings

Alternative Names: aviptadil acetate; DasKloster 1000; DasKloster 1000-01; DasKloster 1000-02; DasKloster 1000-03; DasKloster 1000-04; DK 1000; RLF-100; RLF-100TM; Vasoactive intestinal peptide; Vasoactive intestinal peptide hybrid; VIP; ZYESAMI™

Latest Information Update: 04 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator mondoBIOTECH
  • Developer Centurion Pharma; Lung Rx; mondoBIOTECH; NeuroRX; RELIEF THERAPEUTICS Holding; University of Freiburg
  • Class Anti-inflammatories; Antifibrotics; Antivirals; Gastrointestinal hormones; Neuropeptides; Peptide hormones
  • Mechanism of Action Vasoactive intestinal peptide replacements; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Adult respiratory distress syndrome; Pulmonary sarcoidosis; Acute lung injury; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration SARS-CoV-2 acute respiratory disease
  • Phase III Pulmonary sarcoidosis
  • Phase II COVID 2019 infections
  • Discontinued Adult respiratory distress syndrome; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension

Most Recent Events

  • 28 Apr 2021 Georgian Ministry of Health approves expanded access programme for treatment of SARS-COV-2 acute respiratory disease in Georgia
  • 28 Apr 2021 NeuroRx plans an expanded-access programme for SARS-COV-2 acute respiratory disease in Georgia
  • 26 Apr 2021 Relief Therapeutics plans a phase I trial for SARS-COV-2 acute respiratory disease (Prevention) in Switzerland (Inhalation) (NCT04536350)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top